Towards Healthcare
Generic Pharmaceuticals Contract Manufacturing Market to Reach USD 143.22 Bn b...

Generic Pharmaceuticals Contract Manufacturing Market Transforming with Sterile Injectables

According to market projections, the global generic pharmaceuticals contract manufacturing market, valued at USD 81.24 billion in 2025, is anticipated to reach USD 143.22 billion by 2035, growing at a CAGR of 5.85% over the next decade. Day by day, the globe is increasingly demanding affordable drugs, including diverse biologics. North America registered dominance due to the expansion of complex therapies.

Content

  • Last Updated: 04 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The generic pharmaceuticals contract manufacturing market stands at USD 85.99 billion in 2026 and is expected to reach USD 143.22 billion by 2035, growing at a CAGR of 5.85% from 2025 to 2035.

North America is currently leading the generic pharmaceuticals contract manufacturing market share by 38% due to the increasing demand for inexpensive drugs and complex therapies.

The generic pharmaceuticals contract manufacturing market includes 5 segments such as by service type, by drug type, by formulation, by end-user industry, and by region.

Some key players include Lonza Group, Thermo Fisher Scientific (Patheon), Catalent, Samsung Biologics, and WuXi AppTec.

Key trends include the increasing demand for complex therapies, growth in sterile injectables, and innovations in AI tools.

The main aim is to allow healthcare providers to prescribe effective treatments at minimal expense.

US FDA, EMA, CDSCO, PIB, NIH, MedlinePlus.gov, HHS.gov, TGA.
Any Questions